A diversified pipeline with a singular focus on patient need

We are building a diverse portfolio of product candidates designed to address the
unmet medical needs of patients with cancer and to maximize our opportunities for
clinical and commercial success.
PROGRAM THERAPEUTIC AREA   PRECLINICAL PHASE I PHASE II PIVOTAL/
PHASE III
APPROVED (U.S.)
ADCETRIS™
(brentuximab vedotin)
 
Brentuximab VedotinPost-transplant HL relapse prevention (AETHERA trial) 
 
Relapsed/refractory CD30-positive non-Hodgkin lymphomas 
  
CD30-positive non-lymphoma malignancies 
  
Retreatment of hematologic malignancies 
  
Front-line HL (+chemotherapy) 
   
Front-line CD30+ mature T-cell malignancies (+chemotherapy) 
   
SGN-75CD70+ renal cell carcinoma and
non-Hodgkin lymphoma
 
   
ASG-5MEPancreatic cancer 
   
Prostate cancer 
   
ASG-22MESolid tumors 
   
SGN-CD19ACD19+ hematologic malignancies 
    
ADC
Collaborations
12 clinical-stage ADC programs in hematologic malignancies and solid tumors 
  
Antibody-drug conjugate  
ADC collaborator programs
Privacy Policy  |  Legal Notice